Mirae Asset Global Investments
KDNY

Mirae Asset Global Investments’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Mirae Asset Global Investments’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-34,677
Closed -$1.33M – 2673
2023
Q2 		$1.33M Buy
34,677
+3,392
+11% +$87.1K ﹤0.01% 1409
2023
Q1 		$724K Buy
31,285
+6,872
+28% +$164K ﹤0.01% 1720
2022
Q4 		$640K Buy
24,413
+4,526
+23% +$100K ﹤0.01% 1746
2022
Q3 		$391K Buy
19,887
+6,753
+51% +$135K ﹤0.01% 2021
2022
Q2 		$229K Buy
+13,134
New +$206K ﹤0.01% 2101

Mirae Asset Global Investments's KDNY Position: Q3 2023 in Review

Mirae Asset Global Investments sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 34,677 shares — an estimated $1.33M sold.

Mirae Asset Global Investments first reported a position in KDNY in Q2 2022 and held it in 5 quarters. The position peaked at $1.33M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Mirae Asset Global Investments reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Mirae Asset Global Investments sold 34,677 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.33M.
  • Mirae Asset Global Investments first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Mirae Asset Global Investments's Chinook Therapeutics, Inc. Common Stock position peaked at $1.33M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Mirae Asset Global Investments's 13F filing for Q3 2023, filed 26 Oct 2023.